minomic logo2

 

The Minomic International Board has extensive experience in management, corporate finance, commercialisation of technologies and biotechnology.

Board members and Officeholders include: 

Mr. Jim Green (Executive Chairman)

Mr Green serves as Executive Chairman of Minomic International Ltd. He has strong business development and commercial skills.

By profession a pharmacist, he continues to be involved in the development and operation of a variety of business concerns including three medical centres as well as public relations and media, function centres and retail distribution.

 

 

 

 

Dr Brad Walsh (Chief Scientific Officer)

Dr Walsh has 25 years experience in the biotechnology business and has enjoyed a successful career commercialising immunoassay kits and proteomics technologies and consumables as well as bioinformatics software. His products are being sold and supplied by major us corporations like Waters and Bio-Rad.

Before founding Minomic he was general manager of a not-for-profit public entity called the Australian Proteome Analysis Facility. This was a multi-million dollar facility established in 1995 by the Federal Government. Prior to this he led research groups in public institutions such as CSIRO, universities and hospitals. With his background and having successfully guided Minomic and MPL through six of the most turbulent years in biotech, both industry and government have eagerly sought his opinion as a thought leader and technologist. He has won prizes for the products being developed by the Company and was responsible for putting MPL on the 2006 business review weekly upstarts list of 200 fastest growing start-up companies.

 

David Burdis (Non-Executive Director) B.Bus

Mr Burdis is a qualified accountant and has worked in the chemical, telecommunications and financial services industries.  He has held various senior/board positions, for both listed and unlisted companies, in Australia, the United Kingdom and Hong Kong including GFA International Limited, Swire Blanch Limited and OAMPS Limited.  During his career he has been regularly involved in corporate acquisitions, divestitures and restructuring.  Mr Burdis is the controlling shareholder of Qualita Management Pty Limited, a company providing outsourced management services to leading professional firms, including Ernst & Young and McGrathNicol and Government.

 

 

Mr. Raymore Millard (Non-Executive Director)

Mr Millard is consultant with extensive experience in providing strategic advice to both listed and unlisted companies in Australia and overseas. He has assisted various companies in raising seed capital and with their ultimate listing. He is similarly assisting the Company.

 

 

 

 

Scientific Advisory Panel

Minomic formed a Scientific Advisory Panel (SAP) in 2009. The SAP’s mission is to:

  • Provide critical appraisal of scientific milestone achievements
  • Offer strategic scientific direction to assist in the company’s future endeavors
  • Ensure rigorous and ongoing challenge of the research programs
  • Examine continued viability of projects against such milestones
  • Assess alternative approaches to projects existing and new
  • Assess project competitiveness and alignment with company focus.

The current members of the SAP are:


Name

Affiliation

Dr Peter French (Chairman)

Benitec Ltd

Prof Mark Willcox

Brien Holden Vision Institute, University of NSW

Prof Pam Russell AM

Australian Prostate Cancer Research Centre - Queensland University of Technology

Associate Prof Stuart Cordwell

School of Microbiology and Molecular Biology, University of Sydney

Associate Prof Paul Cozzi

Specialist Urologist, St George Hospital and The Mater Private Hospital

 

 

 

PROSTATE CANCER TESTING SET TO INCREASE
Prostate Cancer tests are set to increase dramatically with the aid of a new diagnostic being developed...

 
Read More :
 

MINOMIC INTERNATIONAL TO COMMERCIALISE PROSTATE CANCER AND DIABETES (TYPE 2) DIAGNOSTICS
Minomic International Limited has commenced its international marketing....

 
Read More :